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Introduction {#sec1}
============

During winter, community-acquired influenza-like illness (ILI), mostly caused by respiratory viruses, is very common. The most frequent viruses seen in primary care are influenza viruses A/B, rhinovirus, coronavirus, respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) \[[@bib1],[@bib2]\]. In the hospital setting, adults with ILI are commonly tested only for influenza, resulting in limited data concerning other respiratory viruses. The use of multiplex reverse transcription polymerase chain reaction (RT-PCR) allows identification of multiple viruses simultaneously but remains a second-line test in non-immunocompromised patients in emergency departments because of its cost and the limited therapeutic options \[[@bib3]\].

Human MPV, discovered in 2001, is phylogenetically similar to RSV and has been frequently found to be associated with respiratory tract illnesses \[[@bib1],[@bib4],[@bib5]\]. Its circulation occurs with a seasonal distribution from January to March in the Northern hemisphere, often overlapping or following RSV infection season \[[@bib6],[@bib7]\]. Human MPV is a major paediatric respiratory pathogen \[[@bib8]\] but can affect all age groups, especially persons with chronic conditions \[[@bib9]\], leading to diverse clinical presentation from upper respiratory tract symptoms to severe pneumonia \[[@bib10],[@bib11]\].

While hMPV is known to contribute substantially to the burden of wintertime respiratory illnesses in adults \[[@bib12]\], data on its frequency and comparison with other respiratory viruses in large adult populations are scarce.

We aimed to (a) describe the clinical characteristics and outcome of hMPV infection and (b) compare hMPV with influenza and RSV infections in adults hospitalized for community-acquired ILI in France in winter between 2012 and 2018.

Methods {#sec2}
=======

Study design {#sec2.1}
------------

We performed a post hoc, retrospective analysis of the FLUVAC study. FLUVAC is a French prospective case-test negative design study evaluating influenza vaccine effectiveness on influenza-associated hospitalization conducted in five (2012/13, 2015/16 to 2017/18) or six (2013/14 to 2014/15) teaching hospitals. All adults hospitalized for at least 24 h for ILI during the influenza circulation period, with symptom onset \<7 days before screening, were included in FLUVAC. ILI was defined according to the European Centre for Disease Prevention and Control (ECDC) definition \[[@bib13]\] as a combination of the following: (a) at least one of the following systemic symptoms -- fever or feverishness, headache, myalgia or malaise; and (b) at least one of the following respiratory symptoms -- cough, sore throat or dyspnea. Patients with contra-indication for influenza immunization, those who had previously tested positive for influenza virus in the same season and those without a French social security affiliation were excluded. Each participant was interviewed, and nasopharyngeal samples were obtained at enrolment to screen for influenza and other respiratory viruses.

In the present study, we included all the patients from the first six FLUVAC seasons (2012/13, 2013/14, 2014/15, 2015/16, 2016/17, 2017/18) for whom virologic results on respiratory viruses were available ([Fig. 1](#fig1){ref-type="fig"} ).Fig. 1Flowchart. hMPV, human metapneumovirus; ILI, influenza-like illness; RSV, respiratory syncytial virus.Fig. 1

Outcomes {#sec2.2}
--------

The primary outcome was the prevalence of confirmed hMPV infection in patients hospitalized with ILI. Secondary outcomes were the demographic characteristics, chronic underlying diseases and treatments, clinical presentation of the ILI episode and complications, intensive care unit admission or death in patients with hMPV infections.

Microbiological data {#sec2.3}
--------------------

Respiratory viruses were identified using multiplex RT-PCR performed on nasopharyngeal swabs. Clinical bronchoalveolar lavage fluid samples and tracheal aspirates were also tested. Samples were first tested in the virology laboratory of each participating hospital using real-time (RT) influenza A and B PCR after manual nucleic acid extraction. All samples were then sent to the French National Influenza Reference Centre (CNR-Lyon) for influenza confirmation and screening for other respiratory viruses (adenoviruses, bocaviruses, hMPV, picornavirus, RSV, coronaviruses, parainfluenza viruses (since 2013)) by RT-PCR using the Respiratory Multiwell System r-gene® on an ABI 7300 analyser between 2012/13 and 2014/15. From 2015/16, all the virology laboratories of the five sites used the same Eurobio kit and only B lineage was provided by the CNR-Lyon.

Statistical analysis {#sec2.4}
--------------------

Quantitative variables were expressed as mean and standard deviation (SD) or median and interquartile range (IQR), and qualitative variables as number and percentage. Qualitative variables were compared using the χ^2^ and Fisher\'s exact tests, as appropriate. Quantitative variables were compared by Wilcoxon rank sum test. Missing data for each variable were excluded from the denominator.

Patients with multiple viral infections were excluded from the analyses. Univariate analysis was used to asses risk factors for the detection of hMPV infection, influenza infection, RSV infection and acute heart failure. We performed two multivariate analyses using a backward stepwise logistic regression model using hMPV test result (positive/negative) and acute heart failure (yes/no) as the dependent variable in the first and second model, respectively. Covariates with a p-value \<0.2 in univariate analysis were tested in the multivariate model. Results from regression models are expressed as crude odds ratios (OR) and adjusted ORs (aOR) with 95% CI. A p-value of \<0.05 was considered statistically significant. Analyses were performed using R software (Version 1.1.463).

Ethics {#sec2.5}
------

The FLUVAC study (clinicaltrials.gov [NCT02027233](NCT02027233){#intref0010}) followed Good Epidemiological and Clinical Practices in Clinical Research, and the Declaration of Helsinki, and was approved by the regional ethics committees. All the study participants gave their informed consent for respiratory virus testing.

Results {#sec3}
=======

Comparison of hMPV+ and hMPV- patients {#sec3.1}
--------------------------------------

Of the 3148 patients included in the FLUVAC study, 1604 (51%, 95% CI 49--53) tested positive for at least one respiratory virus. Most had influenza (1123/1604, 70%, 95% CI 68--72), while 167 had picornavirus (10%, 95% CI 9--12), 145 had RSV (9%, 95% CI 8--10), 100 had hMPV (6%, 95% CI 5--7), 38 had adenovirus (2%, 95% CI 2--3) and 23 had bocavirus (1%, 95% CI 1--2) ([Fig. 1](#fig1){ref-type="fig"}, [Supplementary Table S1](#appsec1){ref-type="sec"}). Ten of the 100 hMPV infections (10%) were co-infection cases with at least one other virus: three with influenza A virus, one with coronavirus, one with both influenza A virus and coronavirus, two with picornavirus, one with parainfluenza virus, one with adenovirus and one with RSV.

Overall, 3% (95% CI 3--4) of people with ILI symptoms (90/3148) tested positive for hMPV. Peak hMPV detection occurred between mid-January and mid-February ([Supplementary Figs S1, S2](#appsec1){ref-type="sec"}). While patients with hMPV infections were generally older than those without (median age 78 years (IQR 70--86) vs 71 years (IQR 57--83), p \< 0.001), other demographic characteristics were similar. Most patients with hMPV presented at least one chronic condition (81%, 73/90), mostly cardiac (50%, 45/90) and respiratory (44%, 40/90) chronic diseases, 17% under immunosuppressive treatment (15/90), 14% active smokers (12/87) and 41% (37/90) hospitalized in the 12 months preceding the study ([Table 1](#tbl1){ref-type="table"} ).Table 1Clinical characteristics and outcomes of hospitalized patients infected with human Metapneumovirus compared with patients without human metapneumovirus, 2012--2018Table 1hMPV-(*n* = 3048)hMPV+ (*n* = 90)Univariate analysisMultivariate analysisCrude ORpAdjusted ORpBaseline characteristicsGender Women, *n* (%)1390/3048 (46%)50/90 (56%)0.061.5(1.0; 2.3)0.08 Men, *n* (%)1658/3048 (54%)40/90 (44%)Age Median age, years (IQR)71 (56--82)78 (70--86)\<0.001 Age \>65 years, *n* (%)1904/3048 (62%)76/90 (84%)\<0.0012.9(1.6; 5.7)0.0013.3(1.9; 6.1)\<0.001Median BMI, kg/m^2^ (IQR)24.8 (21.5--28.5)25.4 (21.1--29.3)Smoking status Smoker, *n* (%)641/293812/87 (14%)0.070.9(0.5; 1.7)0.84 Ex-smoker, *n* (%)973/293828/87 (32%)0.93 Non-smoker, *n* (%)1324/293847/87 (54%)0.12Chronic diseases (at least one), *n* (%)2428/3048 (80%)73/90 (81%)0.74 Chronic respiratory disease, *n* (%)1361/3048 (45%)40/90 (44%)0.96 Chronic heart disease, *n* (%)1267/3048 (42%)45/90 (50%)0.121.1(0.7; 1.8)0.57 Diabetes, *n* (%)714/3048 (23%)18/90 (20%)0.52 Chronic renal failure, *n* (%)468/3048 (15%)9/90 (10%)0.170.5(0.2; 1.0)0.08 Cancer, *n* (%)515/3048 (17%)13/90 (14%)0.45 Cirrhosis, *n* (%)109/3035 (4%)4/90 (4%)0.55Immunosuppressive treatment, *n* (%)514/3043 (17%)15/90 (17%)0.85Pregnancy, *n* (% of women of childbearing age)28/339 (8%)01Influenza vaccination, *n* (%)1418/3011 (47%)52/90 (58%)0.031.1(0.7; 1.7)0.69Hospitalization in the previous 12 months, *n* (%)1405/3031 (46%)37/90 (41%)0.33Presence of child/children \<5 years in the household, *n* (%)182/3025 (6%)5/90 (6%)0.80Clinical presentationMedian time from symptom onset to hospitalization, days (IQR)2 (1--3)2 (1--3)0.7Symptoms Fever or feverishness, *n* (%)2562/3045 (84%)79/90 (88%)0.40 Cough, *n* (%)2360/3045 (78%)75/90 (83%)0.181.5(0.9; 2.7)0.18 Dyspnea, *n* (%)1739/2199 (79%)76/90 (84%)0.54 Weakness/malaise, *n* (%)821/3041 (27%)13/90 (14%)0.0070.5(0.2; 0.8)0.010.4(0.2; 0.8)0.008 Headache, *n* (%)755/3032 (25%)16/90 (18%)0.080.8(0.4; 1.4)0.44 Myalgia, *n* (%)734/3029 (24%)19/90 (21%)0.45 Sore throat, *n* (%)439/3024 (15%)8/90 (9%)0.100.8(0.3; 1.5)0.48OutcomeAt least one complication during the hospital stay, *n* (%)1648/3148 (52%)56/90 (62%)0.13 Pneumonia∗, *n* (%)918/3124 (29%)32/89 (36%)0.27 Respiratory failure, *n* (%)873/3124 (28%)32/89 (36%)0.17 Acute heart failure, *n* (%)420/3122 (13%)22/89 (25%)0.004 Acute respiratory distress syndrome, *n* (%)257/3123 (8%)8/89 (9%)0.85Median length of stay, days (IQR)5 (3--9)7 (4--13)0.50ICU admission after hospitalization in acute care, *n* (%)543/2283 (24%)15/90 (17%)0.60Death, *n* (%)137/3131 (4%)4/90 (4%)1[^2]

The median time from symptom onset to admission was similar between hMPV+ and hMPV- patients (2 days (IQR 1--3)) as well as the main symptoms at inclusion except for weakness/malaise that was less frequent in hMPV + patients (13/90 (14%) vs 27%, p \< 0.007).

There was no difference between hMPV+ and hMPV- groups in terms of median length of stay, number of complications during hospitalization, intensive care unit (ICU) admission and death. However, hMPV + patients were more likely to have an acute heart failure during hospitalization (25% (22/89) vs 14% (377/2722), p \< 0.004).

There was no difference in sociodemographic characteristics, clinical presentation or outcomes between hMPV and viral coinfection and patients with hMPV infections alone.

In the multivariate analysis, when comparing hMPV + patients to all hMPV- patients, age \>65 years (aOR 95% CI 3.3 (1.9; 6.1), p \< 0.001) was significantly associated with hMPV detection. In contrast, the sudden onset of symptoms, defined as the occurrence of malaise/weakness, was associated with the absence of hMPV infection (aOR 95% CI 0.4 (0.2; 0.8), p = 0.008) ([Table 1](#tbl1){ref-type="table"}).

After adjustment for chronic heart disease, age, gender, smoking status and influenza vaccination, hMPV infection was significantly associated with occurrence of acute heart failure during hospitalization (aOR 95% CI 1.8 (1.1; 3.0), p = 0.02).

Comparison of hMPV and influenza + patients {#sec3.2}
-------------------------------------------

In univariate analysis, in comparison with influenza + patients, hMPV + patients were older (median age 78 IQR (70*--*86) vs 69 IQR (54--82) years, respectively, p \< 0.001), more vaccinated against influenza (58% vs 39% respectively, p \< 0.001), presented more dyspnea at inclusion (p = 0.05) but less weakness (p = 0.01), headache (p = 0.01) and sore throat (p = 0.008). They were more likely to present acute heart failure during the hospital stay (p = 0.002). Other outcomes were not significantly different ([Table 2](#tbl2){ref-type="table"} ).Table 2Sociodemographic, clinical characteristics and outcome of hospitalized patients infected with human metapneumovirus, compared with respiratory syncytial virus and influenza virus infected patients, 2012--2018Table 2hMPV+ (*n* = 90)Influenza+ (n = 908)pRSV+ (*n* = 129)pBaseline characteristicsGender Women, *n* (%)50/90 (56%)430/908 (47%)0.1467/129 (52%)0.60 Men, *n* (%)40/90 (44%)478/908 (53%)62/129 (48%)Age Median age, years (IQR)78 (70--86)69 (54--82)\<0.00174 (64--84)0.06 Age \>65 years, *n* (%)76/90 (84%)538/908 (59%)\<0.00195/129 (74%)0.06Median BMI, kg/m^2^ (IQR)24.8 (21.5--28.5)25.1 (22.1--28.4)0.8524.6 (21.6--28.8)0.91Smoking status Smoker, *n* (%)12/87 (14%)178/874 (21%)0.1231/126 (25%)0.05 Ex-smoker, *n* (%)28/87 (32%)260/874 (30%)0.7244/126 (35%)0.70 Non-smoker, *n* (%)47/87 (54%)420/874 (49%)0.3751/126 (40%)0.05Chronic diseases (at least one), *n* (%)73/90 (81%)678/908 (75%)0.18117/129 (91%)0.04 Chronic respiratory disease, *n* (%)40/90 (44%)344/908 (38%)0.2270/129 (54%)0.15 Chronic heart disease, *n* (%)45/90 (50%)362/908 (40%)0.0664/129 (50%)0.96 Diabetes, *n* (%)18/90 (20%)204/908 (22%)0.5930/129 (23%)0.57 Chronic renal failure, *n* (%)9/90 (10%)116/908 (13%)0.4526/129 (20%)0.04 Cancer, *n* (%)13/90 (14%)131/908 (14%)0.9933/129 (26%)0.05 Cirrhosis, *n* (%)4/90 (4%)28/922 (3%)0.524/129 (3%)0.60Immunosuppressive treatment, *n* (%)15/90 (17%)151/904 (17%)0.9926/128 (20%)0.50Pregnancy, *n* (% of women of childbearing age)013/123 (11%)1.0001.00Influenza vaccination, *n* (%)52/90 (58%)351/919 (39%)\<0.00170/126 (56%)0.68Hospitalization in the previous 12 months, *n* (%)37/90 (41%)360/908 (40%)0.7964/129 (50%)0.21Presence of child/children \<5 years in the household, *n* (%)5/90 (6%)69/915 (8%)0.678/129 (6%)0.84Clinical presentationMedian time from symptom onset to hospitalization, days (IQR)2 (1--3)2 (1--4)0.232 (1--3)0.7Symptoms Fever or feverishness, *n* (%)79/90 (88%)811/907 (89%)0.63109/128 (85%)0.58 Cough, *n* (%)75/90 (83%)784/908 (86%)0.43106/128 (83%)0.92 Dyspnea, *n* (%)76/90 (84%)650/908 (71%)0.05112/128 (88%)0.42 Weakness/malaise, *n* (%)13/90 (14%)244/904 (27%)0.0129/128 (23%)0.13 Headache, *n* (%)16/90 (18%)277/902 (31%)0.0130/128 (23%)0.31 Myalgia, *n* (%)19/90 (21%)260/897 (29%)0.1119/128 (15%)0.23 Sore throat, *n* (%)8/90 (9%)184/901 (20%)0.00822/126 (17%)0.07OutcomeAt least one complication during the hospital stay, *n* (%)56/90 (62%)473/908 (52%)0.0785/129 (66%)0.58 Pneumonia, *n* (%)32/89 (36%)257/904 (28%)0.1450/128 (39%)0.64 Respiratory failure, *n* (%)32/89 (36%)254/904 (28%)0.1247/128 (37%)0.91 Acute heart failure, *n* (%)22/89 (25%)114/903 (13%)0.00221/128 (16%)0.13 Acute respiratory distress syndrome, *n* (%)8/89 (9%)83/904 (9%)0.9515/128 (12%)0.52Median length of stay, days (IQR)7 (4--13)6 (3--10)0.067 (5--14)0.50ICU admission after hospitalization in acute care, *n* (%)15/90 (17%)155/908 (17%)0.8833/128 (26%)0.20Death, *n* (%)4/90 (4%)36/906 (4%)0.789/129 (7%)0.44[^3]

In the final model from multivariate analysis, in comparison with influenza + patients, hMPV + patients were more frequently \>65 years old (aOR 3.3 (1.9--6.3), *P* \< 0.001).

Comparison of hMPV+ and RSV + patients {#sec3.3}
--------------------------------------

In univariate analysis, hMPV + patients had less chronic disease (p = 0.04), including chronic renal failure (p = 0.04) and cancer (p = 0.05) and were less likely to smoke (p = 0.05) than RSV + patients.

In the final multivariate model, in comparison with RSV + patients, hMPV + patients had less cancer (aOR = 0.4 (0.2--0.9), p = 0.02) and were less likely to smoke (aOR = 0.5 (0.2--0.9), *P* = 0.04). Clinical presentation and outcomes were similar between the two groups ([Table 2](#tbl2){ref-type="table"}).

Discussion {#sec4}
==========

In our post hoc analysis of 3148 hospitalized adult patients with community-acquired ILI, hMPV was found in 3% of the samples. These patients were older, had chronic conditions, frequent respiratory and cardiac chronic diseases, and frequently presented complications. This prevalence is consistent with several studies that found hMPV in 3--6% of adult patients with lower respiratory tract infection in primary care \[[@bib1],[@bib14], [@bib15], [@bib16]\] and in 6% of patients hospitalized for acute respiratory infection (ARI) \[[@bib17]\]. This frequency may vary according to the inclusion criteria, especially temperature cut-off, as hMPV infection frequently causes non-febrile illness \[[@bib5]\].

Our hospitalized hMPV + adults were mostly older and/or high-risk patients as previously described in the literature \[[@bib5],[@bib10],[@bib18], [@bib19], [@bib20]\]. Complications were frequent (62%), as well as ICU admission (17%) and death (4%). These rates were similar to those of the 91 hospitalized patients with hMPV from the Walsh et al. study in 2008 in the USA \[[@bib10]\], but lower than those of the 128 critically ill adults with hMPV infection (31% required ICU admission and 8% died) from the Hasvold et al. study in 2016 \[[@bib20]\].

The majority of hMPV + patients presented several respiratory signs (cough, dyspnea), whereas sudden onset of symptoms was associated with the absence of hMPV infection. There were differences in clinical presentation between hMPV + patients and influenza + patients (less frequent constitutional symptoms (headache, weakness, myalgia) but more dyspnea) but not between hMPV + patients and RSV + patients. These points emphasize the difficulty in distinguishing between respiratory viruses based on clinical signs alone and question the relevance of the current ILI definition to detect hMPV infection.

Interestingly, we also found that hMPV + patients were older and presented more chronic cardiac conditions and acute heart failure during the hospitalization than influenza + patients. Although, influenza \[[@bib21]\] and RSV \[[@bib22]\] are known to worsen heart failure, no study has specifically assessed hMPV \[[@bib21],[@bib22]\]. In our study, hMPV infection was independently associated with the occurrence of acute heart failure.

Several limitations should be acknowledged. First, we enrolled patients during influenza virus circulation but hMPV circulation does not always match that of influenza. Second, we had no data to support causality between the detection of hMPV in nasopharyngeal samples and the ILI hospital admission. Other pathogens such as respiratory bacteria may have been involved and hMPV may have been a concomitant infectious agent with no role in the symptoms reported. The absence of data on bacteriological results prevents us from addressing this issue. Finally, although asymptomatic carriage of hMPV appears to be uncommon \[[@bib23]\], we had no control population (i.e. hospitalized adults without ILI symptoms) to help evaluate hMPV pathogenicity.

In conclusion, adult hMPV infections concerned 3% of patients hospitalized with ILI in tertiary care hospitals over six consecutive influenza seasons in France. Most of the patients were older, had associated chronic conditions and developed pulmonary and cardiac complications. The relation between hMPV infection and worsening of heart failure needs further investigation. These at-risk populations would benefit from the development of antivirals and vaccines targeting hMPV.

Transparency declaration {#sec5}
========================

The authors declare no competing interest related to the study. P.L. has received personal fees and non-financial support from Pfizer and Sanofi Pasteur. O.L. is an investigator for clinical trials sponsored by Janssen, GSK, Pfizer, Sanofi Pasteur and MSD and received travel support to attend scientific meetings from pharmaceutical companies. The current work received no funding. However, the study sites received funding from 10.13039/100014588Sanofi Pasteur, Sanofi Pasteur 10.13039/100007054MSD and 10.13039/100008897Janssen for the FLUVAC study. Vaccine producers had no role in the study design, data analysis, decision to publish or preparation of the manuscript.

Authors\' contributions {#sec6}
=======================

P.L. and O.L. conceptualized the study. P.L. developed the methodology. P.M. did the analysis. P.L. and P.M. wrote the original manuscript. N.L., F.G., F.L., Z.L., P.V., X.D., D.P., S.A., S.R., G.L., A.S.L., V.F., N.H., B.L. and F.C. critically reviewed the manuscript. O.L. supervised the research.

Appendix A. Supplementary data {#appsec1}
==============================

The following are the Supplementary data to this article:Multimedia component 1Multimedia component 1 Multimedia component 2Multimedia component 2

We thank Sarah Kabani for her editing assistance.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.cmi.2020.04.005>.

[^1]: These authors contributed equally to this work.

[^2]: BMI, body mass index; hMPV, human metapneumovirus; ICU, intensive care unit; IQR, interquartile range; OR, odds ratio.

[^3]: BMI, body mass index; hMPV, human metapneumovirus; ICU, intensive care unit; IQR, interquartile range; RSV, respiratory syncytial virus.
